-
公开(公告)号：US20140228368A1
公开(公告)日：2014-08-14
申请号：US14239603
申请日：2012-08-20
IPC分类号： C07D487/04 , C07D417/14 , C07D401/14
CPC分类号： C07D487/04 , A61K31/506 , C07D239/47 , C07D401/14 , C07D413/14 , C07D417/14 , C07D471/04
摘要： The present invention is directed to pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
摘要翻译： 本发明涉及可用作治疗与磷酸二酯酶10（PDE10）相关的中枢神经系统疾病的治疗剂的嘧啶化合物。 本发明还涉及这些化合物用于治疗神经和精神疾病如精神分裂症，精神病或亨廷顿病以及与纹状体功能减退或基底神经节功能障碍相关的疾病的用途。
-
公开(公告)号：US20130203756A1
公开(公告)日：2013-08-08
申请号：US13825616
申请日：2011-10-24
申请人： Jamie L. Bunda , Christopher D. Cox , Vadim Y. Dudkin , Hannah D. Fiji , Michael J. Kelly , Mark E. Layton , Joseph E. Pero , William D. Shipe , Justin T. Sheen
发明人： Jamie L. Bunda , Christopher D. Cox , Vadim Y. Dudkin , Hannah D. Fiji , Michael J. Kelly , Mark E. Layton , Joseph E. Pero , William D. Shipe , Justin T. Sheen
IPC分类号： C07D403/06 , C07D519/00 , C07D417/14 , C07D413/14 , C07D471/04
CPC分类号： C07D403/06 , A61K31/44 , C07D413/14 , C07D417/14 , C07D471/04 , C07D519/00
摘要： The present invention is directed to isoindolinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
摘要翻译： 本发明涉及可用作治疗与磷酸二酯酶10（PDE10）相关的中枢神经系统疾病的治疗剂的异吲哚啉酮化合物。 本发明还涉及这些化合物用于治疗神经和精神疾病如精神分裂症，精神病或亨廷顿病以及与纹状体功能减退或基底神经节功能障碍相关的疾病的用途。
-
公开(公告)号：US20130158056A1
公开(公告)日：2013-06-20
申请号：US13820648
申请日：2011-09-26
IPC分类号： C07D513/04 , C07D495/04 , C07D417/14 , C07D471/04 , C07D401/14
CPC分类号： A61K31/505 , A61K31/506 , A61K31/513 , C07D239/30 , C07D239/48 , C07D239/52 , C07D239/56 , C07D401/14 , C07D403/12 , C07D403/14 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D495/04 , C07D513/04
摘要： The present invention is directed to 2-alkoxy pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
摘要翻译： 本发明涉及可用作治疗与磷酸二酯酶10（PDE10）相关的中枢神经系统疾病的治疗剂的2-烷氧基嘧啶化合物。 本发明还涉及这些化合物用于治疗神经和精神疾病如精神分裂症，精神病或亨廷顿病以及与纹状体功能减退或基底神经节功能障碍相关的疾病的用途。
-
公开(公告)号：US08389720B2
公开(公告)日：2013-03-05
申请号：US13127898
申请日：2009-11-03
申请人： James C. Barrow , Mark T. Bilodeau , Christopher D. Cox , John C. Hartnett , Nathan R. Kett , Yiwei Li , Peter J. Manley , Jeffrey Melamed , William D. Shipe , B. Wesley Trotter , Amy Zartman
发明人： James C. Barrow , Mark T. Bilodeau , Christopher D. Cox , John C. Hartnett , Nathan R. Kett , Yiwei Li , Peter J. Manley , Jeffrey Melamed , William D. Shipe , B. Wesley Trotter , Amy Zartman
IPC分类号： A61K31/551 , A61K31/5355 , A61K31/497 , A61K31/519 , A61K31/4412 , A61K31/4704 , C07D243/08 , C07D413/14 , C07D471/04 , C07D401/14 , C07D401/12 , C07D405/14
CPC分类号： A61K31/47 , C07D401/12 , C07D405/12
摘要： The present invention is directed to quinolone compounds which are antagonists of neuropeptide S receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which the neuropeptide S receptor is involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the neuropeptide S receptor is involved.
摘要翻译： 本发明涉及作为神经肽S受体的拮抗剂的喹诺酮化合物，其可用于治疗或预防神经和精神疾病以及涉及神经肽S受体的疾病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及神经肽S受体的疾病中的用途。
-
公开(公告)号：US20110263643A1
公开(公告)日：2011-10-27
申请号：US13125191
申请日：2009-10-15
IPC分类号： A61K31/4545 , A61P25/20 , A61K31/4709 , C07D401/14 , A61K31/4725
CPC分类号： C07D401/14
摘要： The present invention is directed to 2,3-disubstituted piperidine amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
摘要翻译： 本发明涉及作为食欲素受体的拮抗剂的2,3-二取代哌啶酰胺化合物，其可用于治疗或预防涉及食欲素受体的神经和精神病症和疾病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及食欲肽受体的疾病中的用途。
-
公开(公告)号：US20110212946A1
公开(公告)日：2011-09-01
申请号：US13127898
申请日：2009-11-03
申请人： James C. Barrow , Mark T. Bilodeau , Christopher D. Cox , John C. Hartnett , Nathan R. Kett , Yiwei Li , Peter J. Manley , Jeffrey Melamed , William D. Shipe , B. Wesley Trotter , Amy Zartman
发明人： James C. Barrow , Mark T. Bilodeau , Christopher D. Cox , John C. Hartnett , Nathan R. Kett , Yiwei Li , Peter J. Manley , Jeffrey Melamed , William D. Shipe , B. Wesley Trotter , Amy Zartman
IPC分类号： A61K31/4704 , C07D405/14 , A61K31/496 , A61K31/55 , C07D401/12 , A61K31/4709 , C07D413/12 , A61K31/5377 , C07D215/227 , A61P25/00
CPC分类号： A61K31/47 , C07D401/12 , C07D405/12
摘要： The present invention is directed to quinolone compounds which are antagonists of neuropeptide S receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which the neuropeptide S receptor is involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the neuropeptide S receptor is involved.
摘要翻译： 本发明涉及作为神经肽S受体的拮抗剂的喹诺酮化合物，其可用于治疗或预防神经和精神疾病以及涉及神经肽S受体的疾病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及神经肽S受体的疾病中的用途。
-
公开(公告)号：US20110207715A1
公开(公告)日：2011-08-25
申请号：US13125174
申请日：2009-10-15
IPC分类号： A61K31/553 , C07D403/10 , A61K31/55 , A61P25/00 , C07D413/10
CPC分类号： C07D223/12 , C07D401/14 , C07D403/10 , C07D413/10 , C07D413/14 , C07D417/10 , C07D417/14
摘要： The present invention is directed to disubstituted azepan and oxazepan amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
摘要翻译： 本发明涉及作为食欲素受体的拮抗剂的二取代氮杂环庚烷和氧氮杂环酰胺化合物，其可用于治疗或预防涉及食欲素受体的神经和精神病症和疾病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及食欲肽受体的疾病中的用途。
-
公开(公告)号：US08785467B2
公开(公告)日：2014-07-22
申请号：US13820648
申请日：2011-09-26
IPC分类号： A01N43/54 , A61K31/505 , A61K31/506 , C07D239/30 , C07D239/48 , C07D239/52 , C07D239/56
CPC分类号： A61K31/505 , A61K31/506 , A61K31/513 , C07D239/30 , C07D239/48 , C07D239/52 , C07D239/56 , C07D401/14 , C07D403/12 , C07D403/14 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D495/04 , C07D513/04
摘要： The present invention is directed to 2-alkoxy pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
摘要翻译： 本发明涉及可用作治疗与磷酸二酯酶10（PDE10）相关的中枢神经系统疾病的治疗剂的2-烷氧基嘧啶化合物。 本发明还涉及这些化合物用于治疗神经和精神疾病如精神分裂症，精神病或亨廷顿病以及与纹状体功能减退或基底神经节功能障碍相关的疾病的用途。
-
公开(公告)号：US20130225583A1
公开(公告)日：2013-08-29
申请号：US13877704
申请日：2011-10-17
申请人： Gerald W. Shipps, JR. , Berengere Sauvagnat , Jack Bracken , William T. McElroy , Christopher D. Cox , Ginny Ho , Georgia Mcgaughey
发明人： Gerald W. Shipps, JR. , Berengere Sauvagnat , Jack Bracken , William T. McElroy , Christopher D. Cox , Ginny Ho , Georgia Mcgaughey
IPC分类号： C07D403/14 , C07D401/14 , C07D403/04 , C07D471/04 , C07D413/14 , C07D417/14
CPC分类号： C07D403/14 , C07D249/14 , C07D401/14 , C07D403/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04
摘要： The present invention is directed to substituted amino-triazolyl compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
摘要翻译： 本发明涉及可用作治疗与磷酸二酯酶10（PDE10）相关的中枢神经系统疾病的治疗剂的取代的氨基 - 三唑基化合物。 本发明还涉及这些化合物用于治疗神经和精神疾病如精神分裂症，精神病或亨廷顿病以及与纹状体功能减退或基底神经节功能障碍相关的疾病的用途。
-
公开(公告)号：US08357700B2
公开(公告)日：2013-01-22
申请号：US13125191
申请日：2009-10-15
IPC分类号： A61K31/04 , C07D215/38
CPC分类号： C07D401/14
摘要： The present invention is directed to 2,3-disubstituted piperidine amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
摘要翻译： 本发明涉及作为食欲素受体的拮抗剂的2,3-二取代哌啶酰胺化合物，其可用于治疗或预防涉及食欲素受体的神经和精神病症和疾病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及食欲肽受体的疾病中的用途。
-
-
-
-
-
-
-
-
-
搜索结果
72 条记录 (耗时 0.068 秒)
